Management and prophylaxis of infections after BMT/SCT

Alison Gail Freifeld, Reinhold Munker, Kerry Atkinson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Management of febrile neutropenia page 357 Empiric antibiotic treatment for febrile neutropenia 357 Management of continued febrile neutropenia in the absence of documented infection (fever of unknown origin) 359 Treatment of specific infections and localizing signs and symptoms of infection 360 Prevention of infections in HSCT patients 366 Antiviral prophylaxis 368 Transplant-related considerations for hepatitis B and C 369 Management of infections 370 Management of specific infections 370 Interstitial pneumonitis 373 Further reading 378 Management of febrile neutropenia Empiric antibiotic treatment for febrile neutropenia Neutropenia as a consequence of cytoreductive chemotherapy is associated with increased risk of serious infections. This risk starts to increase when the absolute neutrophil count (ANC) decreases to less than 1000 cells/mm3 and further increases dramatically when it is less than 500 cells/mm3. A bloodstream infection develops in approximately 10%–20% with neutrophil counts less than 100 cells/mm3. Less often, pneumonia, cellulitis, catheter-related infections, or herpesvirus reactivations occur, causing fever. Fungal infections rarely cause initial fever during neutropenia; they typically occur after a week or more of neutropenia. Notably, fewer than half of all initial episodes of fever and neutropenia are “fever of undetermined origin” (FUO), with no identifiable source of infection despite examination, radiographs, and cultures. FUO patients cannot be reliably distinguished from those with documented infections on presentation, through signs or symptoms or blood tests. Therefore, all neutropenic patients should be treated immediately with a specific regimen of broad-spectrum antibiotics if there is any suspicion of infection, and especially if fever occurs, as there is danger of rapidly progressive sepsis.

Original languageEnglish (US)
Title of host publicationThe BMT Data Book, 2nd Edition
PublisherCambridge University Press
Pages357-378
Number of pages22
ISBN (Electronic)9780511575525
ISBN (Print)9780521711005
DOIs
StatePublished - Jan 1 2009

Fingerprint

Febrile Neutropenia
Infection
Fever
Neutropenia
Anti-Bacterial Agents
Signs and Symptoms
Neutrophils
Fever of Unknown Origin
Catheter-Related Infections
Cellulitis
Mycoses
Herpesviridae
Interstitial Lung Diseases
Hematologic Tests
Hepatitis C
Hepatitis B
Antiviral Agents
Reading
Sepsis
Pneumonia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Freifeld, A. G., Munker, R., & Atkinson, K. (2009). Management and prophylaxis of infections after BMT/SCT. In The BMT Data Book, 2nd Edition (pp. 357-378). Cambridge University Press. https://doi.org/10.1017/CBO9780511575525.025

Management and prophylaxis of infections after BMT/SCT. / Freifeld, Alison Gail; Munker, Reinhold; Atkinson, Kerry.

The BMT Data Book, 2nd Edition. Cambridge University Press, 2009. p. 357-378.

Research output: Chapter in Book/Report/Conference proceedingChapter

Freifeld, AG, Munker, R & Atkinson, K 2009, Management and prophylaxis of infections after BMT/SCT. in The BMT Data Book, 2nd Edition. Cambridge University Press, pp. 357-378. https://doi.org/10.1017/CBO9780511575525.025
Freifeld AG, Munker R, Atkinson K. Management and prophylaxis of infections after BMT/SCT. In The BMT Data Book, 2nd Edition. Cambridge University Press. 2009. p. 357-378 https://doi.org/10.1017/CBO9780511575525.025
Freifeld, Alison Gail ; Munker, Reinhold ; Atkinson, Kerry. / Management and prophylaxis of infections after BMT/SCT. The BMT Data Book, 2nd Edition. Cambridge University Press, 2009. pp. 357-378
@inbook{3504435d28c44a1790d1dd94dfea2fd1,
title = "Management and prophylaxis of infections after BMT/SCT",
abstract = "Management of febrile neutropenia page 357 Empiric antibiotic treatment for febrile neutropenia 357 Management of continued febrile neutropenia in the absence of documented infection (fever of unknown origin) 359 Treatment of specific infections and localizing signs and symptoms of infection 360 Prevention of infections in HSCT patients 366 Antiviral prophylaxis 368 Transplant-related considerations for hepatitis B and C 369 Management of infections 370 Management of specific infections 370 Interstitial pneumonitis 373 Further reading 378 Management of febrile neutropenia Empiric antibiotic treatment for febrile neutropenia Neutropenia as a consequence of cytoreductive chemotherapy is associated with increased risk of serious infections. This risk starts to increase when the absolute neutrophil count (ANC) decreases to less than 1000 cells/mm3 and further increases dramatically when it is less than 500 cells/mm3. A bloodstream infection develops in approximately 10{\%}–20{\%} with neutrophil counts less than 100 cells/mm3. Less often, pneumonia, cellulitis, catheter-related infections, or herpesvirus reactivations occur, causing fever. Fungal infections rarely cause initial fever during neutropenia; they typically occur after a week or more of neutropenia. Notably, fewer than half of all initial episodes of fever and neutropenia are “fever of undetermined origin” (FUO), with no identifiable source of infection despite examination, radiographs, and cultures. FUO patients cannot be reliably distinguished from those with documented infections on presentation, through signs or symptoms or blood tests. Therefore, all neutropenic patients should be treated immediately with a specific regimen of broad-spectrum antibiotics if there is any suspicion of infection, and especially if fever occurs, as there is danger of rapidly progressive sepsis.",
author = "Freifeld, {Alison Gail} and Reinhold Munker and Kerry Atkinson",
year = "2009",
month = "1",
day = "1",
doi = "10.1017/CBO9780511575525.025",
language = "English (US)",
isbn = "9780521711005",
pages = "357--378",
booktitle = "The BMT Data Book, 2nd Edition",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Management and prophylaxis of infections after BMT/SCT

AU - Freifeld, Alison Gail

AU - Munker, Reinhold

AU - Atkinson, Kerry

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Management of febrile neutropenia page 357 Empiric antibiotic treatment for febrile neutropenia 357 Management of continued febrile neutropenia in the absence of documented infection (fever of unknown origin) 359 Treatment of specific infections and localizing signs and symptoms of infection 360 Prevention of infections in HSCT patients 366 Antiviral prophylaxis 368 Transplant-related considerations for hepatitis B and C 369 Management of infections 370 Management of specific infections 370 Interstitial pneumonitis 373 Further reading 378 Management of febrile neutropenia Empiric antibiotic treatment for febrile neutropenia Neutropenia as a consequence of cytoreductive chemotherapy is associated with increased risk of serious infections. This risk starts to increase when the absolute neutrophil count (ANC) decreases to less than 1000 cells/mm3 and further increases dramatically when it is less than 500 cells/mm3. A bloodstream infection develops in approximately 10%–20% with neutrophil counts less than 100 cells/mm3. Less often, pneumonia, cellulitis, catheter-related infections, or herpesvirus reactivations occur, causing fever. Fungal infections rarely cause initial fever during neutropenia; they typically occur after a week or more of neutropenia. Notably, fewer than half of all initial episodes of fever and neutropenia are “fever of undetermined origin” (FUO), with no identifiable source of infection despite examination, radiographs, and cultures. FUO patients cannot be reliably distinguished from those with documented infections on presentation, through signs or symptoms or blood tests. Therefore, all neutropenic patients should be treated immediately with a specific regimen of broad-spectrum antibiotics if there is any suspicion of infection, and especially if fever occurs, as there is danger of rapidly progressive sepsis.

AB - Management of febrile neutropenia page 357 Empiric antibiotic treatment for febrile neutropenia 357 Management of continued febrile neutropenia in the absence of documented infection (fever of unknown origin) 359 Treatment of specific infections and localizing signs and symptoms of infection 360 Prevention of infections in HSCT patients 366 Antiviral prophylaxis 368 Transplant-related considerations for hepatitis B and C 369 Management of infections 370 Management of specific infections 370 Interstitial pneumonitis 373 Further reading 378 Management of febrile neutropenia Empiric antibiotic treatment for febrile neutropenia Neutropenia as a consequence of cytoreductive chemotherapy is associated with increased risk of serious infections. This risk starts to increase when the absolute neutrophil count (ANC) decreases to less than 1000 cells/mm3 and further increases dramatically when it is less than 500 cells/mm3. A bloodstream infection develops in approximately 10%–20% with neutrophil counts less than 100 cells/mm3. Less often, pneumonia, cellulitis, catheter-related infections, or herpesvirus reactivations occur, causing fever. Fungal infections rarely cause initial fever during neutropenia; they typically occur after a week or more of neutropenia. Notably, fewer than half of all initial episodes of fever and neutropenia are “fever of undetermined origin” (FUO), with no identifiable source of infection despite examination, radiographs, and cultures. FUO patients cannot be reliably distinguished from those with documented infections on presentation, through signs or symptoms or blood tests. Therefore, all neutropenic patients should be treated immediately with a specific regimen of broad-spectrum antibiotics if there is any suspicion of infection, and especially if fever occurs, as there is danger of rapidly progressive sepsis.

UR - http://www.scopus.com/inward/record.url?scp=84927961775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927961775&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511575525.025

DO - 10.1017/CBO9780511575525.025

M3 - Chapter

AN - SCOPUS:84927961775

SN - 9780521711005

SP - 357

EP - 378

BT - The BMT Data Book, 2nd Edition

PB - Cambridge University Press

ER -